(Q24241080)

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibers in 114 biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Stages in fibre breakdown in Duchenne muscular dystrophy. An electron-microscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Regulation of membrane-mediated chronic muscle degeneration in dystrophic hamsters by calcium-channel blockers: diltiazem, nifedipine and verapamil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Experimental mouse muscle damage: the importance of external calcium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Elevated subsarcolemmal Ca2+ in mdx mouse skeletal muscle fibers detected with Ca2+-activated K+ channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Cochrane Database of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Delayed diagnosis of Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Dystrophin protects the sarcolemma from stresses developed during muscle contraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Reduction in intracellular calcium levels inhibits myoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Allocation concealment in randomised trials: defending against deciphering

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Increased calcium influx in dystrophic muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

Clinical trial in Duchenne dystrophy. I. The design of the protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

A trial of flunarizine in the treatment of Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Clinical investigation in Duchenne dystrophy. VI. Double-blind controlled trial of nifedipine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Effect of dantrolene in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

A double-blind placebo controlled trial of diltiazem in Duchenne dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Acute respiratory failure following intravenous verapamil in Duchenne's muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Neuromuscular block by verapamil and diltiazem and inhibition of acetylcholine release

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

In vivo effects of three calcium blockers on chickens with inherited muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Possible systemic smooth muscle layer dysfunction due to a deficiency of dystrophin in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Effect of chronic administration of verapamil in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Selective potentiation of subtetanic and tetanic contractions by the calcium-channel antagonist nifedipine in the rat diaphragm preparation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Influence of calcium channel blocker drugs in neuromuscular transmission

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Impaired primary hemostasis with normal platelet function in Duchenne muscular dystrophy during highly-invasive spinal surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Verapamil in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Muscular degeneration in the absence of dystrophin is a calcium-dependent process

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Effects of Long-term Treatment with Verapamil on Left Ventricular Function and Myocardial Blood Flow in Patients with Dilated Cardiomyopathy Without Overt Heart Failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Cardiac and pulmonary complications in Duchenne's progressive muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021

Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004571.PUB2

7 January 2021